<DOC>
	<DOCNO>NCT00890279</DOCNO>
	<brief_summary>This phase II study examines safety efficacy combination therapy hypertension patient autosomal dominant polycystic kidney disease ( ADPKD ) . This study examine safety efficacy combination therapy imidapril ( ACEI ) cilnidipine ( CCB ) ADPKD patient whose blood pressure control 120/80 mmHg candesartan ( ARB ) alone .</brief_summary>
	<brief_title>Efficacy Safety Study Second-Line Treatment Hypertension With Autosomal Dominant Polycystic Kidney Disease ( ADPKD )</brief_title>
	<detailed_description>Maximum dosage candesartan 8 mg/day . Dosage imidapril range 2.5-10 mg/day . Dosage cilnidipine range 5-20mg/day .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Imidapril</mesh_term>
	<mesh_term>Cilnidipine</mesh_term>
	<criteria>ADPKD patient Blood pressure measure outpatient set 120/80 mmHg Age 20 60 year old eGFR 30 ml/min/1.73m2 Patients give informed consent Patients severe cardiovascular hepatic disorder Patients complication central nervous vascular disorder Women breast feeding female childbearing potential use acceptable contraceptive method Patients currently engage experimental protocol Patients intracranial aneurysma Patients must use diuretic Allergic patient Candesartan Cilnidipine Patients whose hypertension control medication protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin-II Receptor Blocker</keyword>
	<keyword>Calcium Channel Blocker</keyword>
	<keyword>Angiotensin convert enzyme inhibitor</keyword>
	<keyword>Kidney Volume</keyword>
	<keyword>eGFR</keyword>
</DOC>